OSA-Direct
Tuesday, 11 Dec 2018

eMagin signs licensing agreement for immersive headset intellectual property

Our immersive headset has four times the resolution of alternative cellphone based VR headsets and provides a more realistic, 'screen-door'- free image

6 Jan 2016 | Editor

eMagin Corp. has signed a non-exclusive intellectual property (IP) licensing agreement for its unique 4 MegaPixel per eye immersive virtual reality headset technology with an undisclosed company.

The deal includes an upfront licensing fee of US$1,000,000 and a commitment to use eMagin’s 2,000 x 2,000 pixel full colour displays in the company’s headsets.

According to eMagin the company’s OLED microdisplays are an ideal choice for the emerging Virtual Reality and Augmented Reality markets with features such as their speed (which helps prevent nausea), small size, low power consumption, high brightness and high contrast. These features make eMagin’s microdisplays a better choice than alternative liquid crystal based display technologies like LCOS or LCD.

Andrew G. Sculley, CEO of eMagin Corp., "This licensing agreement confirms that our immersive headset technology is unique in the VR market." Andrew added, "Our immersive headset has four times the resolution of alternative cellphone based VR headsets and provides a more realistic, 'screen-door'- free image. This agreement also demonstrates that eMagin’s OLED microdisplays are the right choice for VR applications, giving eMagin the opportunity to jump into the market with its highest resolution microdisplay offering."

   


About eMagin

A leader in OLED microdisplay technology, OLED microdisplay manufacturing know-how and mobile display systems, eMagin manufactures high-resolution OLED microdisplays and integrates them with magnifying optics to deliver virtual images comparable to large-screen computer and television displays in portable, low power consumption, lightweight personal displays. eMagin microdisplays provide near-eye imagery in a variety of products from military, industrial, medical and consumer OEMs.

Source: eMagin